<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-137650" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Carcinoembryonic Antigen</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kankanala</surname>
            <given-names>Vijaya L.</given-names>
          </name>
          <aff>Presbyterian Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mukkamalla</surname>
            <given-names>Shiva Kumar R.</given-names>
          </name>
          <aff>Presbyterian Healthcare Services</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Vijaya Kankanala declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shiva Kumar Mukkamalla declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>23</day>
          <month>1</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-137650.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Carcinoembryonic antigen (CEA) is a non-specific serum biomarker that is elevated in various malignancies such as colorectal cancer, medullary thyroid cancer, breast cancer, mucinous ovarian cancer, etc. It was first detected in colon cancer cells by Freedman and Gold&#x000a0;and eventually was found in various other epithelial cells in the&#x000a0;stomach<bold>,</bold> tongue, esophagus, cervix, and prostate.<xref ref-type="bibr" rid="article-137650.r1">[1]</xref>&#x000a0;It is a glycoprotein with a molecular weight of 200 kDa and is normally derived from embryonic endodermal epithelium in the fetus, controlled by fetal oncogenes. It usually disappears from serum after birth; however, small quantities of CEA may remain in colon tissue. CEA and related genes (29 of which 18 are normally expressed) constitute the CEA family in human beings and are clustered on chromosome 19q13.2.<xref ref-type="bibr" rid="article-137650.r2">[2]</xref>&#x000a0;Since it is associated with various types of malignant and nonmalignant medical conditions (Table 1), elevated serum CEA is not a definitive marker of a particular site of&#x000a0;cancer origin.<xref ref-type="bibr" rid="article-137650.r3">[3]</xref> Therefore, it is not recommended for routine screening or diagnosis of cancers by itself. CEA is currently being studied as a target for various cancer-directed therapies.<xref ref-type="bibr" rid="article-137650.r4">[4]</xref><xref ref-type="bibr" rid="article-137650.r5">[5]</xref></p>
        <table-wrap id="article-137650.table0" position="float" orientation="portrait">
          <caption>
            <title>Table: 1 Malignant and nonmalignant conditions associated with elevated CEA&#x000a0;</title>
          </caption>
          <table style="height: 491px;">
            <tbody>
              <tr>
                <td style="width: 340.5px;" rowspan="1" colspan="1">
<p><bold>Malignant Conditions</bold></p>
</td>
                <td style="width: 412.5px;" rowspan="1" colspan="1">
<p><bold>Nonmalignant Conditions</bold></p>
</td>
              </tr>
              <tr>
                <td style="width: 340.5px;" rowspan="1" colspan="1">
<p>Colorectal cancer</p>
<p>Prostate cancer</p>
<p>Breast</p>
<p>Ovarian cancer</p>
<p>Pancreatic cancer</p>
<p>Mucinous adenocarcinoma of the cervix</p>
<p>Lung cancer</p>
<p>Thyroid cancer</p>
</td>
                <td style="width: 412.5px;" rowspan="1" colspan="1">
<p><bold>Liver&#x000a0;disorders</bold></p>
<p>Alcoholic liver disease</p>
<p>Chronic liver disease&#x000a0;</p>
<p>Primary biliary cirrhosis</p>
<p>Obstructive jaundice</p>
<p><bold>&#x000a0;</bold></p>
<p><bold>Gastrointestinal disorders</bold></p>
<p>Peptic ulcer</p>
<p>Inflammatory bowel disease</p>
<p>Pancreatitis</p>
<p>Diverticulitis</p>
<p><bold>Others</bold></p>
<p>Smoking</p>
<p>Renal failure</p>
<p>Fibrocystic breast disease</p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="article-137650.s2" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>CEA belongs to the immunoglobulin family and is called CEA-related cell adhesion molecules. CEA&#x000a0;is closely associated with various functions of endothelial cells, including adhesion, proliferation, and migration of cells both in vivo and in vitro.<xref ref-type="bibr" rid="article-137650.r6">[6]</xref>&#x000a0;It is present on the endoluminal side of the cell membrane of normal cells and is thought to inhibit apoptosis and hence is involved in tumor pathogenesis. Although CEA is predominantly associated with gastrointestinal tumors, literature shows its close correlation with breast, lung, ovarian, mucinous adenocarcinomas of the cervix, and thyroid cancers.</p>
      </sec>
      <sec id="article-137650.s3" sec-type="Specimen Requirements and Procedure">
        <title>Specimen Requirements and Procedure</title>
        <p>The test for CEA measurement is usually conducted on a blood sample collected by the health care personnel/phlebotomist. A small quantity of the blood (3&#x000a0;to 5 cc) is collected in a vial and sent to the laboratory to estimate the CEA Level. The risks associated with such a procedure are minimal, including needle site pain/stinging, bruising, bleeding, or infections. The procedure takes less than&#x000a0;5 minutes and does not need specific requirements, such as fasting. Occasionally, a CEA test is performed on bodily fluids such as pleural fluid, peritoneal fluid, or, rarely, cerebrospinal fluid.</p>
      </sec>
      <sec id="article-137650.s4" sec-type="Testing Procedures">
        <title>Testing Procedures</title>
        <p>Many commercially available products utilize different technologies such as sandwiched enzyme-linked immunosorbent assay, immunonephelometry, chemiluminometric immunoassay, immunomagnetic reduction, etc. CEA levels can fluctuate based on the type of testing procedure utilized. Therefore,&#x000a0;discordant serial CEA levels must be carefully correlated with differences in testing procedures. Using monoclonal antibodies directed against the&#x000a0;6 reactive isotopes of CEA in specific assays could result in erroneous findings amongst patients previously treated with monoclonal antibodies.<xref ref-type="bibr" rid="article-137650.r9">[7]</xref></p>
      </sec>
      <sec id="article-137650.s5" sec-type="Interfering Factors">
        <title>Interfering Factors</title>
        <p>CEA is predominantly metabolized in the liver. Therefore, hepatic and biliary dysfunction can be associated with elevated levels, causing false positives. Because of high first-pass hepatic metabolism, significantly elevated levels correspond to CEA-producing tumors or metastases outside portal venous drainage territory. Tumor differentiation can also affect the CEA levels, with higher CEA levels seen in well-differentiated cancers.<xref ref-type="bibr" rid="article-137650.r26">[8]</xref><xref ref-type="bibr" rid="article-137650.r27">[9]</xref>&#x000a0;Amongst benign conditions that affect CEA levels, smoking is&#x000a0;1 of the common causes. It has been established that smoking increases CEA levels.<xref ref-type="bibr" rid="article-137650.r28">[10]</xref><xref ref-type="bibr" rid="article-137650.r29">[11]</xref></p>
      </sec>
      <sec id="article-137650.s6" sec-type="Results, Reporting, and Critical Findings&#x0000d;&#x0000a;">
        <title>Results, Reporting, and Critical Findings
</title>
        <p>
<bold>Ranges</bold>
</p>
        <p>In healthy, non-smoking adults, CEA is considered within normal limits at a level of &#x0003c;=3.0 &#x000b5;g/L. Smokers may have elevated CEA, considered within normal limits at a &#x0003c;5 &#x000b5;g/L level. Pre-treatment serum CEA levels greater than&#x000a0;5 &#x000b5;g/L but less than&#x000a0;10 &#x000b5;g/L suggest localized disease and a low likelihood of recurrence, hence a favorable prognosis. A serum&#x000a0;level of &#x0003e;10 &#x000b5;g/L indicates a higher likelihood of recurrence and poor prognosis. Serum titers of &#x0003e;20 &#x000b5;g/L are usually associated with metastatic disease in breast and colon cancers. However, given the variability in CEA expression or secretion, values &#x0003c;2.5 &#x000b5;g/L do not necessarily rule out primary, recurrent, or metastatic cancers. For colorectal cancers, a CEA threshold of 2.5&#x000a0;&#x000b5;g/L carries a sensitivity of 82% and a specificity of 80%, while a threshold of 10 &#x000b5;g/L carries a sensitivity of 68% and a specificity of 97%.<xref ref-type="bibr" rid="article-137650.r7">[12]</xref></p>
        <p>
<bold>Advantages</bold>
</p>
        <p>Serum-based CEA testing is a cost-effective surveillance method for various cancers and is part of various national and international surveillance guidelines. Along with imaging studies, it is an equally important tool to assess ongoing response to palliative treatments in metastatic cancers. It is very easy and widely available, even in a community setting.</p>
        <p>
<bold>Drawbacks</bold>
</p>
        <p>Due to low sensitivity and specificity, it cannot be used as a screening test to detect malignancies. Although used for detecting the recurrence of cancer after primary surgical and adjuvant treatments, a single value (one-time measurement) is inadequate due to low sensitivity (high false-positive rate), and serial measurements (trend) are essential. Raising CEA cut-off (&#x0003e;10 &#x000b5;g/L) and combining it with other modalities such as CT scans of chest, abdomen, and pelvis at 12 months intervals is recommended instead of using it as a sole test for monitoring recurrence of colorectal cancer. People exposed to certain animal antigens may develop antibodies to CEA that might affect CEA levels and lead to unreliable results. Smokers are highly likely to get false-positive results; therefore, the test is unreliable in active smokers. It is not recommended to use CEA for follow-up in active smokers with colon cancer after primary treatment.</p>
      </sec>
      <sec id="article-137650.s7" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>
<bold>CEA in Colorectal Cancer Diagnosis and Post-Treatment Surveillance to Monitor Recurrence/Residual Tumor</bold>
</p>
        <p>CEA is a strong prognostic biomarker in patients with colorectal cancer who underwent surgical resection and adjuvant chemotherapy.<xref ref-type="bibr" rid="article-137650.r38">[13]</xref>&#x000a0;Elevated CEA level of &#x0003e;5 &#x000b5;g/L at the time of new diagnosis of colorectal cancer is associated with poor prognosis.<xref ref-type="bibr" rid="article-137650.r39">[14]</xref>&#x000a0;However, normalization of elevated CEA levels after surgery is not associated with a poor prognosis. Hence, routine assessment of CEA before surgical treatment is not indicated, and post-operative detection is usually more useful in detecting recurrence within the first year of surgery and prognostication. Follow-up with CEA level in patients with colorectal cancers after primary treatment was found effective in detecting cancer recurrences that can be treated with curative intent in the follow-up after colorectal surgery (FACS) trial.<xref ref-type="bibr" rid="article-137650.r40">[15]</xref>&#x000a0;The national guidelines in North America and Europe also endorse the measurement of CEA during post-operative follow-up in colorectal cancer.<xref ref-type="bibr" rid="article-137650.r41">[16]</xref><xref ref-type="bibr" rid="article-137650.r42">[17]</xref>&#x000a0;Serial monitoring of CEA is recommended before initiation of treatment and after that every&#x000a0;3 months during active treatment and during active surveillance to assess the response to resection and systemic therapy (chemotherapy/radiotherapy) in colorectal cancer.<xref ref-type="bibr" rid="article-137650.r43">[18]</xref>&#x000a0;</p>
        <p>In colorectal cancer, serum CEA normalizes 6 weeks after the tumor resection. Therefore, persistently elevated CEA levels may indicate residual tumor due to incomplete resection or recurrence of the tumor. Restaging malignancy should be considered if there is persistently rising CEA above baseline, potentially suggesting cancer progression. CEA levels should not be checked too early, i.e., 4 to 6 weeks before starting a new therapy, as some chemotherapeutic agents may elevate CEA falsely.<xref ref-type="bibr" rid="article-137650.r44">[19]</xref><xref ref-type="bibr" rid="article-137650.r45">[20]</xref>&#x000a0;The increasing level of CEA precedes the clinical recurrence, leading to early suspicion/detection of recurrence. As endorsed by the American Society of Clinical Oncology guidelines (2006 and 2013 updates), for patients with stage II and stage III colorectal cancer who are candidates for surgery or chemotherapy, post-operative/post-treatment CEA measurement should be done every&#x000a0;3 months for at least&#x000a0;2 years along with annual CT scans, followed by every&#x000a0;6 months for&#x000a0;5 years.<xref ref-type="bibr" rid="article-137650.r46">[21]</xref>&#x000a0;The sensitivity and specificity of serial measurement of CEA in detecting recurrent colorectal cancer are approximately 80% and 70%, respectively.<xref ref-type="bibr" rid="article-137650.r34">[22]</xref>&#x000a0;It has the advantage of providing a lead time of about&#x000a0;5 months compared to other diagnostic methods for detecting recurrence. Early detection increases the chance of surgical cure by timely resection of recurrent tumors.</p>
        <p>
<bold>Post-Resection Detection of Liver Metastasis/Oligometastases</bold>
</p>
        <p>CEA measurement is the most sensitive detector of liver metastasis from colorectal cancers that can be resected surgically.<xref ref-type="bibr" rid="article-137650.r47">[23]</xref>&#x000a0;There is evidence that colon cancer patients with liver metastasis with preoperative CEA less than or equal to 30 &#x000b5;g/L are more likely to have resectable metastatic lesions and, hence, more prolonged survival.<xref ref-type="bibr" rid="article-137650.r48">[24]</xref>&#x000a0;When monitored along with CT scans, CEA has proven to detect metastasis in a surgically curable stage more effectively&#x000a0;than either modality alone.</p>
        <p>
<bold>CEA in Medullary Carcinoma of the Thyroid</bold>
</p>
        <p>According to the revised guidelines of the American Thyroid Association for the management of medullary thyroid carcinoma, CEA is not a specific biomarker for medullary carcinoma. However, measuring CEA levels is very helpful in assessing the disease progression and post-thyroidectomy monitoring. According to Chen et al, the North American Society for Neuroendocrine Tumors (NANETS) guidelines, preoperative levels above 30&#x000a0;&#x000b5;g/L indicate the extra-thyroid spread of the disease. In contrast, levels greater than 100 &#x000b5;g/L are associated with invasive disease, including lymph node involvement and distant metastasis.<xref ref-type="bibr" rid="article-137650.r49">[25]</xref>&#x000a0;It is recommended to plan surgical treatment with total thyroidectomy, central cervical lymph node dissection, and unilateral lateral cervical lymph node dissection when CEA levels are greater than 30 &#x000b5;g/L. Pre-targeted radioimmunotherapy (radiolabeled monoclonal antibodies against CEA) is a promising treatment modality for medullary carcinoma of the thyroid.&#x000a0;Patients with persistent CEA levels after colon cancer surgery and a negative diagnostic workup for metastatic disease should steer the diagnostic workup towards medullary carcinoma of the thyroid, including calcitonin measurement and neck ultrasound.<xref ref-type="bibr" rid="article-137650.r50">[26]</xref></p>
        <p>
<bold>CEA in Ascitic Fluid</bold>
</p>
        <p>CEA levels are proven to be of some value in cases where ascitic fluid cytology is inconclusive. Serum levels greater than 5 &#x000b5;g/L are&#x000a0;suggestive of&#x000a0;carcinoma. However,&#x000a0;higher values were common in cancers with peritoneal involvement, with a sensitivity of 51 % and specificity of 97% for carcinomatosis (p &#x0003c;0.01).<xref ref-type="bibr" rid="article-137650.r51">[27]</xref></p>
        <p>
<bold>CEA in Pleural Fluid</bold>
</p>
        <p>An elevated CEA level in a patient with pleural fluid and negative cytology precludes more invasive modalities, such as VATS-guided biopsy, to rule out malignant etiology. In contrast, lower CEA levels may support a close follow-up.<xref ref-type="bibr" rid="article-137650.r52">[28]</xref></p>
        <p>
<bold>CEA in Non-Small-Cell Lung Cancer (NSCLC)</bold>
</p>
        <p>Due to limited preoperative imaging sensitivity, 30% of patients with stage I NSCLC have positive N2-N3 nodes at the time of diagnosis. Preoperative CEA levels help identify patients with advanced disease that might be missed on imaging. Higher CEA levels correlate with advanced stage, nodal metastasis, and poor survival. It potentially identifies the patient population who would benefit from invasive mediastinal lymph node staging by mediastinoscopy or endoscopic ultrasound and benefit from neoadjuvant chemotherapy or chemoradiotherapy rather than upfront surgery.<xref ref-type="bibr" rid="article-137650.r53">[29]</xref><xref ref-type="bibr" rid="article-137650.r54">[30]</xref></p>
        <p>
<bold>CEA in Breast Cancer</bold>
</p>
        <p>Currently, routine use of CEA in screening for breast cancer is not recommended as per ASCO due to limited sensitivity and specificity. However, in addition to CA 15-3 and CA 27.29, CEA and diagnostic imaging can be used to monitor patients with metastatic disease receiving active therapy.<xref ref-type="bibr" rid="article-137650.r55">[31]</xref></p>
      </sec>
      <sec id="article-137650.s8">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=137650&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=137650">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/137650/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=137650">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-137650.s9">
        <title>References</title>
        <ref id="article-137650.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>T&#x000e9;llez-Avila</surname>
                <given-names>FI</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Osogobio</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>[The carcinoembryonic antigen: apropos of an old friend].</article-title>
            <source>Rev Invest Clin</source>
            <year>2005</year>
            <season>Nov-Dec</season>
            <volume>57</volume>
            <issue>6</issue>
            <fpage>814</fpage>
            <page-range>814-9</page-range>
            <pub-id pub-id-type="pmid">16708907</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hammarstr&#x000f6;m</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues.</article-title>
            <source>Semin Cancer Biol</source>
            <year>1999</year>
            <month>Apr</month>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>67</fpage>
            <page-range>67-81</page-range>
            <pub-id pub-id-type="pmid">10202129</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Meng</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>XL</given-names>
              </name>
            </person-group>
            <article-title>A nanobody targeting carcinoembryonic antigen as a promising molecular probe for non-small cell lung cancer.</article-title>
            <source>Mol Med Rep</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>625</fpage>
            <page-range>625-630</page-range>
            <pub-id pub-id-type="pmid">28586008</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>L&#x000e1;zaro-Gorines</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ruiz-de-la-Herr&#x000e1;n</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Navarro</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sanz</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>&#x000c1;lvarez-Vallina</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez-Del-Pozo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gavilanes</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Lacadena</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>A novel Carcinoembryonic Antigen (CEA)-Targeted Trimeric Immunotoxin shows significantly enhanced Antitumor Activity in Human Colorectal Cancer Xenografts.</article-title>
            <source>Sci Rep</source>
            <year>2019</year>
            <month>Aug</month>
            <day>12</day>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>11680</fpage>
            <pub-id pub-id-type="pmid">31406218</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shinmi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nakano</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mitamura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Suzuki-Imaizumi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Iwano</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Isoda</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Enokizono</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shiraishi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Arakawa</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tomizuka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Masuda</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Novel anticarcinoembryonic antigen antibody-drug conjugate has antitumor activity in the existence of soluble antigen.</article-title>
            <source>Cancer Med</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>6</volume>
            <issue>4</issue>
            <fpage>798</fpage>
            <page-range>798-808</page-range>
            <pub-id pub-id-type="pmid">28211613</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zi-Yang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kaixun</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Dongling</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chengbin</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Jimei</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Caojin</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Carcinoembryonic antigen levels are increased with pulmonary output in pulmonary hypertension due to congenital heart disease.</article-title>
            <source>J Int Med Res</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>48</volume>
            <issue>11</issue>
            <fpage>300060520964378</fpage>
            <pub-id pub-id-type="pmid">33203284</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nicholson</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Shinkins</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pathiraja</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>NW</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Mallett</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Perera</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Primrose</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Mant</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Blood CEA levels for detecting recurrent colorectal cancer.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2015</year>
            <month>Dec</month>
            <day>10</day>
            <volume>2015</volume>
            <issue>12</issue>
            <fpage>CD011134</fpage>
            <pub-id pub-id-type="pmid">26661580</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r8">
          <label>8</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Mahadevarao Premnath</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zubair</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <chapter-title>Laboratory Evaluation of Tumor Biomarkers</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>10</month>
            <day>28</day>
            <pub-id pub-id-type="pmid">37983320</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hammarstrom</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shively</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Paxton</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Beatty</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Larsson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ghosh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bormer</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Buchegger</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mach</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Burtin</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Antigenic sites in carcinoembryonic antigen.</article-title>
            <source>Cancer Res</source>
            <year>1989</year>
            <month>Sep</month>
            <day>01</day>
            <volume>49</volume>
            <issue>17</issue>
            <fpage>4852</fpage>
            <page-range>4852-8</page-range>
            <pub-id pub-id-type="pmid">2474375</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hedin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Carlsson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Berglund</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hammarstr&#x000f6;m</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>A monoclonal antibody-enzyme immunoassay for serum carcinoembryonic antigen with increased specificity for carcinomas.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>1983</year>
            <month>Jun</month>
            <volume>80</volume>
            <issue>11</issue>
            <fpage>3470</fpage>
            <page-range>3470-4</page-range>
            <pub-id pub-id-type="pmid">6344085</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuroki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kuroki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Koga</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Matsuoka</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Monoclonal antibodies to carcinoembryonic antigen: a systematic analysis of antibody specificities by using related normal antigens and evidence for allotypic determinants on carcinoembryonic antigen.</article-title>
            <source>J Immunol</source>
            <year>1984</year>
            <month>Oct</month>
            <volume>133</volume>
            <issue>4</issue>
            <fpage>2090</fpage>
            <page-range>2090-7</page-range>
            <pub-id pub-id-type="pmid">6206151</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nishizono</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Iida</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kawada</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Murakami</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ashihara</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Okada</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Rapid and sensitive chemiluminescent enzyme immunoassay for measuring tumor markers.</article-title>
            <source>Clin Chem</source>
            <year>1991</year>
            <month>Sep</month>
            <volume>37</volume>
            <issue>9</issue>
            <fpage>1639</fpage>
            <page-range>1639-44</page-range>
            <pub-id pub-id-type="pmid">1716538</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wei</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Qian</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Multianalyte immunoassay chip for detection of tumor markers by chemiluminescent and colorimetric methods.</article-title>
            <source>Anal Bioanal Chem</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>401</volume>
            <issue>10</issue>
            <fpage>3269</fpage>
            <page-range>3269-74</page-range>
            <pub-id pub-id-type="pmid">21928078</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gao</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Deng</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Qu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Measurement of Carcinoembryonic Antigen in Clinical Serum Samples Using a Centrifugal Microfluidic Device.</article-title>
            <source>Micromachines (Basel)</source>
            <year>2018</year>
            <month>Sep</month>
            <day>17</day>
            <volume>9</volume>
            <issue>9</issue>
            <pub-id pub-id-type="pmid">30424403</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nagasaki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kuroki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Matsumoto</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Murakami</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Omoda</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kondo</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Jinnai</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Takaoka</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Matsuoka</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>An enzyme immunoassay for carcinoembryonic antigen (CEA) with homogeneous reactivity to different CEA preparations and low cross-reactivity with CEA-related normal antigens.</article-title>
            <source>J Immunol Methods</source>
            <year>1993</year>
            <month>Jun</month>
            <day>18</day>
            <volume>162</volume>
            <issue>2</issue>
            <fpage>235</fpage>
            <page-range>235-45</page-range>
            <pub-id pub-id-type="pmid">7686200</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tate</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Interferences in immunoassay.</article-title>
            <source>Clin Biochem Rev</source>
            <year>2004</year>
            <month>May</month>
            <volume>25</volume>
            <issue>2</issue>
            <fpage>105</fpage>
            <page-range>105-20</page-range>
            <pub-id pub-id-type="pmid">18458713</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wauthier</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Plebani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Favresse</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Interferences in immunoassays: review and practical algorithm.</article-title>
            <source>Clin Chem Lab Med</source>
            <year>2022</year>
            <month>May</month>
            <day>25</day>
            <volume>60</volume>
            <issue>6</issue>
            <fpage>808</fpage>
            <page-range>808-820</page-range>
            <pub-id pub-id-type="pmid">35304841</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ross</surname>
                <given-names>GMS</given-names>
              </name>
              <name>
                <surname>Filippini</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nielen</surname>
                <given-names>MWF</given-names>
              </name>
              <name>
                <surname>Salentijn</surname>
                <given-names>GI</given-names>
              </name>
            </person-group>
            <article-title>Unraveling the Hook Effect: A Comprehensive Study of High Antigen Concentration Effects in Sandwich Lateral Flow Immunoassays.</article-title>
            <source>Anal Chem</source>
            <year>2020</year>
            <month>Dec</month>
            <day>01</day>
            <volume>92</volume>
            <issue>23</issue>
            <fpage>15587</fpage>
            <page-range>15587-15595</page-range>
            <pub-id pub-id-type="pmid">33185097</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rey</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>O'Dell</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Erickson</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Mitigating the Hook Effect in Lateral Flow Sandwich Immunoassays Using Real-Time Reaction Kinetics.</article-title>
            <source>Anal Chem</source>
            <year>2017</year>
            <month>May</month>
            <day>02</day>
            <volume>89</volume>
            <issue>9</issue>
            <fpage>5095</fpage>
            <page-range>5095-5100</page-range>
            <pub-id pub-id-type="pmid">28388030</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Armbruster</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Alexander</surname>
                <given-names>DB</given-names>
              </name>
            </person-group>
            <article-title>Sample to sample carryover: a source of analytical laboratory error and its relevance to integrated clinical chemistry/immunoassay systems.</article-title>
            <source>Clin Chim Acta</source>
            <year>2006</year>
            <month>Nov</month>
            <volume>373</volume>
            <issue>1-2</issue>
            <fpage>37</fpage>
            <page-range>37-43</page-range>
            <pub-id pub-id-type="pmid">16777083</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kavsak</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Zeidler</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Carryover: More than just a major hangover for the clinical laboratory.</article-title>
            <source>Clin Biochem</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>49</volume>
            <issue>10-11</issue>
            <fpage>735</fpage>
            <page-range>735-6</page-range>
            <pub-id pub-id-type="pmid">27220058</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sturgeon</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Viljoen</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Analytical error and interference in immunoassay: minimizing risk.</article-title>
            <source>Ann Clin Biochem</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>48</volume>
            <issue>Pt 5</issue>
            <fpage>418</fpage>
            <page-range>418-32</page-range>
            <pub-id pub-id-type="pmid">21750113</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kuribayashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Umemori</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ohe</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Asanuma</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>High prevalence of human anti-mouse antibodies in the serum of colorectal cancer patients.</article-title>
            <source>Anticancer Res</source>
            <year>2010</year>
            <month>Oct</month>
            <volume>30</volume>
            <issue>10</issue>
            <fpage>4353</fpage>
            <page-range>4353-6</page-range>
            <pub-id pub-id-type="pmid">21036763</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ward</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Simpson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Boscato</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hickman</surname>
                <given-names>PE</given-names>
              </name>
            </person-group>
            <article-title>The investigation of interferences in immunoassay.</article-title>
            <source>Clin Biochem</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>50</volume>
            <issue>18</issue>
            <fpage>1306</fpage>
            <page-range>1306-1311</page-range>
            <pub-id pub-id-type="pmid">28847718</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lauro</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Corcuff</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Brossaud</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Georges</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>[What to do in the event of a suspicion of analytical interference during an immunoassay?].</article-title>
            <source>Ann Biol Clin (Paris)</source>
            <year>2020</year>
            <month>Feb</month>
            <day>01</day>
            <volume>78</volume>
            <issue>1</issue>
            <fpage>70</fpage>
            <page-range>70-73</page-range>
            <pub-id pub-id-type="pmid">32108582</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siregar</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Sibarani</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Comparison of Carcinoembryonic Antigen Levels Among Degree of Differentiation and Colorectal Cancer's Location in Medan.</article-title>
            <source>Open Access Maced J Med Sci</source>
            <year>2019</year>
            <month>Oct</month>
            <day>30</day>
            <volume>7</volume>
            <issue>20</issue>
            <fpage>3447</fpage>
            <page-range>3447-3450</page-range>
            <pub-id pub-id-type="pmid">32002071</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goslin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Steele</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Corson</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Zamcheck</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Correlation of Plasma CEA and CEA tissue staining in poorly differentiated colorectal cancer.</article-title>
            <source>Am J Med</source>
            <year>1981</year>
            <month>Aug</month>
            <volume>71</volume>
            <issue>2</issue>
            <fpage>246</fpage>
            <page-range>246-53</page-range>
            <pub-id pub-id-type="pmid">6167166</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alexander</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Silverman</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Chretien</surname>
                <given-names>PB</given-names>
              </name>
            </person-group>
            <article-title>Effect of age and cigarette smoking on carcinoembryonic antigen levels.</article-title>
            <source>JAMA</source>
            <year>1976</year>
            <month>May</month>
            <day>03</day>
            <volume>235</volume>
            <issue>18</issue>
            <fpage>1975</fpage>
            <page-range>1975-9</page-range>
            <pub-id pub-id-type="pmid">56468</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fukuda</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Yamakado</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kiyose</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Influence of smoking on serum carcinoembryonic antigen levels in subjects who underwent multiphasic health testing and services.</article-title>
            <source>J Med Syst</source>
            <year>1998</year>
            <month>Apr</month>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>89</fpage>
            <page-range>89-93</page-range>
            <pub-id pub-id-type="pmid">9571515</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nah</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kwon</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>HI</given-names>
              </name>
            </person-group>
            <article-title>Establishment and validation of reference intervals for tumor markers (AFP, CEA, CA19-9, CA15-3, CA125, PSA, HE4, Cyfra 21-1, and ProGRP) in primary care centers in Korea: A cross-sectional retrospective study.</article-title>
            <source>Health Sci Rep</source>
            <year>2023</year>
            <month>Feb</month>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>e1107</fpage>
            <pub-id pub-id-type="pmid">36789402</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Tumor markers in clinical practice: General principles and guidelines.</article-title>
            <source>Indian J Med Paediatr Oncol</source>
            <year>2009</year>
            <month>Jan</month>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-8</page-range>
            <pub-id pub-id-type="pmid">20668599</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Duffy</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Tumor markers in clinical practice: a review focusing on common solid cancers.</article-title>
            <source>Med Princ Pract</source>
            <year>2013</year>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>4</fpage>
            <page-range>4-11</page-range>
            <pub-id pub-id-type="pmid">22584792</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stollberg</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>N&#x000e4;pflin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nagler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Huber</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Are Tumor Marker Tests Applied Appropriately in Clinical Practice? A Healthcare Claims Data Analysis.</article-title>
            <source>Diagnostics (Basel)</source>
            <year>2023</year>
            <month>Nov</month>
            <day>03</day>
            <volume>13</volume>
            <issue>21</issue>
            <pub-id pub-id-type="pmid">37958275</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Duffy</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful?</article-title>
            <source>Clin Chem</source>
            <year>2001</year>
            <month>Apr</month>
            <volume>47</volume>
            <issue>4</issue>
            <fpage>624</fpage>
            <page-range>624-30</page-range>
            <pub-id pub-id-type="pmid">11274010</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hall</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Clarke</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Buchwald</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Eglinton</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wakeman</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Frizelle</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>A Review of the Role of Carcinoembryonic Antigen in Clinical Practice.</article-title>
            <source>Ann Coloproctol</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>35</volume>
            <issue>6</issue>
            <fpage>294</fpage>
            <page-range>294-305</page-range>
            <pub-id pub-id-type="pmid">31937069</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Desai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Guddati</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Carcinoembryonic Antigen, Carbohydrate Antigen 19-9, Cancer Antigen 125, Prostate-Specific Antigen and Other Cancer Markers: A Primer on Commonly Used Cancer Markers.</article-title>
            <source>World J Oncol</source>
            <year>2023</year>
            <month>Feb</month>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>4</fpage>
            <page-range>4-14</page-range>
            <pub-id pub-id-type="pmid">36895994</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Litvak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cercek</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Segal</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Reidy-Lagunes</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Stadler</surname>
                <given-names>ZK</given-names>
              </name>
              <name>
                <surname>Yaeger</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Kemeny</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Weiser</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Pessin</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Saltz</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>False-positive elevations of carcinoembryonic antigen in patients with a history of resected colorectal cancer.</article-title>
            <source>J Natl Compr Canc Netw</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>12</volume>
            <issue>6</issue>
            <fpage>907</fpage>
            <page-range>907-13</page-range>
            <pub-id pub-id-type="pmid">24925201</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ozawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Matsuda</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ishihara</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fukushima</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shimada</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hayama</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nozawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hashiguchi</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>The robust performance of carcinoembryonic antigen levels after adjuvant chemotherapy for the recurrence risk stratification in patients with colorectal cancer.</article-title>
            <source>J Surg Oncol</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>124</volume>
            <issue>1</issue>
            <fpage>97</fpage>
            <page-range>97-105</page-range>
            <pub-id pub-id-type="pmid">33848373</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Konishi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shimada</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tufts</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jimenez-Rodriguez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cercek</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yaeger</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Saltz</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Nash</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Guillem</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Paty</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Garcia-Aguilar</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gonen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Weiser</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Association of Preoperative and Postoperative Serum Carcinoembryonic Antigen and Colon Cancer Outcome.</article-title>
            <source>JAMA Oncol</source>
            <year>2018</year>
            <month>Mar</month>
            <day>01</day>
            <volume>4</volume>
            <issue>3</issue>
            <fpage>309</fpage>
            <page-range>309-315</page-range>
            <pub-id pub-id-type="pmid">29270608</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Primrose</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Perera</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gray</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rose</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fuller</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Corkhill</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mant</surname>
                <given-names>D</given-names>
              </name>
              <collab>FACS Trial Investigators</collab>
            </person-group>
            <article-title>Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial.</article-title>
            <source>JAMA</source>
            <year>2014</year>
            <month>Jan</month>
            <day>15</day>
            <volume>311</volume>
            <issue>3</issue>
            <fpage>263</fpage>
            <page-range>263-70</page-range>
            <pub-id pub-id-type="pmid">24430319</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Benson</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Bekaii-Saab</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Choti</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Engstrom</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Enzinger</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Fakih</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Fenton</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Fuchs</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Grem</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kamel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Leong</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>May</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Mulcahy</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rohren</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Saltz</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shibata</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Skibber</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Small</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Sofocleous</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Venook</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Willett</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Gregory</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Freedman-Cass</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines.</article-title>
            <source>J Natl Compr Canc Netw</source>
            <year>2013</year>
            <month>Feb</month>
            <day>01</day>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>141</fpage>
            <page-range>141-52; quiz 152</page-range>
            <pub-id pub-id-type="pmid">23411381</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r42">
          <label>42</label>
          <element-citation publication-type="book">
            <source>Addendum to clinical guideline 131, Colorectal cancer</source>
            <publisher-name>National Institute for Health and Care Excellence (NICE)</publisher-name>
            <publisher-loc>London</publisher-loc>
            <year>2014</year>
            <month>12</month>
            <pub-id pub-id-type="pmid">31815386</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Locker</surname>
                <given-names>GY</given-names>
              </name>
              <name>
                <surname>Hamilton</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jessup</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Kemeny</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Macdonald</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Somerfield</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Hayes</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Bast</surname>
                <given-names>RC</given-names>
              </name>
              <collab>ASCO</collab>
            </person-group>
            <article-title>ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer.</article-title>
            <source>J Clin Oncol</source>
            <year>2006</year>
            <month>Nov</month>
            <day>20</day>
            <volume>24</volume>
            <issue>33</issue>
            <fpage>5313</fpage>
            <page-range>5313-27</page-range>
            <pub-id pub-id-type="pmid">17060676</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>S&#x000f8;rbye</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Dahl</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to oxaliplatin combination chemotherapy: implications for tumor marker monitoring and guidelines.</article-title>
            <source>J Clin Oncol</source>
            <year>2003</year>
            <month>Dec</month>
            <day>01</day>
            <volume>21</volume>
            <issue>23</issue>
            <fpage>4466</fpage>
            <page-range>4466-7</page-range>
            <pub-id pub-id-type="pmid">14645446</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>S&#x000f8;rbye</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Dahl</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Transient CEA increase at start of oxaliplatin combination therapy for metastatic colorectal cancer.</article-title>
            <source>Acta Oncol</source>
            <year>2004</year>
            <volume>43</volume>
            <issue>5</issue>
            <fpage>495</fpage>
            <page-range>495-8</page-range>
            <pub-id pub-id-type="pmid">15360055</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meyerhardt</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Mangu</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Flynn</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Korde</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Loprinzi</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Minsky</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Petrelli</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Schrag</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Benson</surname>
                <given-names>AB</given-names>
              </name>
              <collab>American Society of Clinical Oncology</collab>
            </person-group>
            <article-title>Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement.</article-title>
            <source>J Clin Oncol</source>
            <year>2013</year>
            <month>Dec</month>
            <day>10</day>
            <volume>31</volume>
            <issue>35</issue>
            <fpage>4465</fpage>
            <page-range>4465-70</page-range>
            <pub-id pub-id-type="pmid">24220554</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arnaud</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Koehl</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Adloff</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Carcinoembryonic antigen (CEA) in diagnosis and prognosis of colorectal carcinoma.</article-title>
            <source>Dis Colon Rectum</source>
            <year>1980</year>
            <month>Apr</month>
            <volume>23</volume>
            <issue>3</issue>
            <fpage>141</fpage>
            <page-range>141-4</page-range>
            <pub-id pub-id-type="pmid">7379666</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bakalakos</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Burak</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>EW</given-names>
              </name>
            </person-group>
            <article-title>Is carcino-embryonic antigen useful in the follow-up management of patients with colorectal liver metastases?</article-title>
            <source>Am J Surg</source>
            <year>1999</year>
            <month>Jan</month>
            <volume>177</volume>
            <issue>1</issue>
            <fpage>2</fpage>
            <page-range>2-6</page-range>
            <pub-id pub-id-type="pmid">10037299</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sippel</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>O'Dorisio</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Vinik</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Lloyd</surname>
                <given-names>RV</given-names>
              </name>
              <name>
                <surname>Pacak</surname>
                <given-names>K</given-names>
              </name>
              <collab>North American Neuroendocrine Tumor Society (NANETS)</collab>
            </person-group>
            <article-title>The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer.</article-title>
            <source>Pancreas</source>
            <year>2010</year>
            <month>Aug</month>
            <volume>39</volume>
            <issue>6</issue>
            <fpage>775</fpage>
            <page-range>775-83</page-range>
            <pub-id pub-id-type="pmid">20664475</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nien</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>TC</given-names>
              </name>
            </person-group>
            <article-title>Biomarkers of medullary thyroid cancer in the prediction of cure after thyroidectomy.</article-title>
            <source>J Formos Med Assoc</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>114</volume>
            <issue>9</issue>
            <fpage>793</fpage>
            <page-range>793-4</page-range>
            <pub-id pub-id-type="pmid">23906686</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guly&#x000e1;s</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kaposi</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Elek</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Szoll&#x000e1;r</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Hjerpe</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Value of carcinoembryonic antigen (CEA) and cholesterol assays of ascitic fluid in cases of inconclusive cytology.</article-title>
            <source>J Clin Pathol</source>
            <year>2001</year>
            <month>Nov</month>
            <volume>54</volume>
            <issue>11</issue>
            <fpage>831</fpage>
            <page-range>831-5</page-range>
            <pub-id pub-id-type="pmid">11684715</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hackner</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Errhalt</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Handzhiev</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Ratio of carcinoembryonic antigen in pleural fluid and serum for the diagnosis of malignant pleural effusion.</article-title>
            <source>Ther Adv Med Oncol</source>
            <year>2019</year>
            <volume>11</volume>
            <fpage>1758835919850341</fpage>
            <pub-id pub-id-type="pmid">31205509</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuo</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Miao</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Chou</surname>
                <given-names>YT</given-names>
              </name>
            </person-group>
            <article-title>Association of Divergent Carcinoembryonic Antigen Patterns and Lung Cancer Progression.</article-title>
            <source>Sci Rep</source>
            <year>2020</year>
            <month>Feb</month>
            <day>07</day>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>2066</fpage>
            <pub-id pub-id-type="pmid">32034239</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nasralla</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Elevated preoperative CEA is associated with subclinical nodal involvement and worse survival in stage I non-small cell lung cancer: a systematic review and meta-analysis.</article-title>
            <source>J Cardiothorac Surg</source>
            <year>2020</year>
            <month>Oct</month>
            <day>15</day>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>318</fpage>
            <pub-id pub-id-type="pmid">33059696</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhao</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Q</given-names>
              </name>
            </person-group>
            <article-title>Association of Preoperative Serum Levels of CEA and CA15-3 with Molecular Subtypes of Breast Cancer.</article-title>
            <source>Dis Markers</source>
            <year>2021</year>
            <volume>2021</volume>
            <fpage>5529106</fpage>
            <pub-id pub-id-type="pmid">34621407</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pillai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Calvert</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Practical considerations for laboratories: Implementing a holistic quality management system.</article-title>
            <source>Front Bioeng Biotechnol</source>
            <year>2022</year>
            <volume>10</volume>
            <fpage>1040103</fpage>
            <pub-id pub-id-type="pmid">36406233</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ben Ayed</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ben Hadj Hmida</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kassis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Damak</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Masmoudi</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>[Quality control in tumor marker values: methology, results and potential problems].</article-title>
            <source>Tunis Med</source>
            <year>2001</year>
            <season>Jun-Jul</season>
            <volume>79</volume>
            <issue>6-7</issue>
            <fpage>341</fpage>
            <page-range>341-7</page-range>
            <pub-id pub-id-type="pmid">11771428</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Teshome</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Worede</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Asmelash</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Total Clinical Chemistry Laboratory Errors and Evaluation of the Analytical Quality Control Using Sigma Metric for Routine Clinical Chemistry Tests.</article-title>
            <source>J Multidiscip Healthc</source>
            <year>2021</year>
            <volume>14</volume>
            <fpage>125</fpage>
            <page-range>125-136</page-range>
            <pub-id pub-id-type="pmid">33488088</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Badrick</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Quality leadership and quality control.</article-title>
            <source>Clin Biochem Rev</source>
            <year>2003</year>
            <month>Aug</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>81</fpage>
            <page-range>81-93</page-range>
            <pub-id pub-id-type="pmid">18568046</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reinauer</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>WG</given-names>
              </name>
            </person-group>
            <article-title>External quality assessment of tumour marker analysis: state of the art and consequences for estimating diagnostic sensitivity and specificity.</article-title>
            <source>Ger Med Sci</source>
            <year>2005</year>
            <month>May</month>
            <day>30</day>
            <volume>3</volume>
            <fpage>Doc02</fpage>
            <pub-id pub-id-type="pmid">19675719</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sturgeon</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Standardization of tumor markers - priorities identified through external quality assessment.</article-title>
            <source>Scand J Clin Lab Invest Suppl</source>
            <year>2016</year>
            <volume>245</volume>
            <fpage>S94</fpage>
            <page-range>S94-9</page-range>
            <pub-id pub-id-type="pmid">27542005</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Rossum</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Holdenrieder</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ballieux</surname>
                <given-names>BEPB</given-names>
              </name>
              <name>
                <surname>Badrick</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Yun</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Thelen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wojtalewicz</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Unsworth</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Vesper</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Cui</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Ramanathan</surname>
                <given-names>LV</given-names>
              </name>
              <name>
                <surname>Sturgeon</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Meng</surname>
                <given-names>QH</given-names>
              </name>
            </person-group>
            <article-title>Investigating the Current Harmonization Status of Tumor Markers Using Global External Quality Assessment Programs: A Feasibility Study.</article-title>
            <source>Clin Chem</source>
            <year>2024</year>
            <month>Apr</month>
            <day>03</day>
            <volume>70</volume>
            <issue>4</issue>
            <fpage>669</fpage>
            <page-range>669-679</page-range>
            <pub-id pub-id-type="pmid">38385453</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Van Rossum</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Holdenrieder</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yun</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Thelen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Unsworth</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Partridge</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cui</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Ramanathan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Meng</surname>
                <given-names>QH</given-names>
              </name>
              <name>
                <surname>Ballieux</surname>
                <given-names>BEPB</given-names>
              </name>
              <name>
                <surname>Sturgeon</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vesper</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>External quality assessment-based tumor marker harmonization simulation; insights in achievable harmonization for CA 15-3 and CEA.</article-title>
            <source>Clin Chem Lab Med</source>
            <year>2024</year>
            <month>Sep</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">39299928</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wagar</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Yuan</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The laboratory and patient safety.</article-title>
            <source>Clin Lab Med</source>
            <year>2007</year>
            <month>Dec</month>
            <volume>27</volume>
            <issue>4</issue>
            <fpage>909</fpage>
            <page-range>909-30, viii-ix</page-range>
            <pub-id pub-id-type="pmid">17950905</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r65">
          <label>65</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Patel</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>DD</given-names>
              </name>
            </person-group>
            <chapter-title>Occupational Safety and Health Administration Rules That Affect Healthcare</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>1</day>
            <pub-id pub-id-type="pmid">32644753</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lunn</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lawler Chemical Resistance Of Gloves</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Laboratory safety.</article-title>
            <source>Curr Protoc Protein Sci</source>
            <year>2002</year>
            <month>Aug</month>
            <volume>Appendix 2</volume>
            <fpage>A.2A.1</fpage>
            <page-range>A.2A.1-A.2A.35</page-range>
            <pub-id pub-id-type="pmid">18429218</pub-id>
          </element-citation>
        </ref>
        <ref id="article-137650.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abu-Siniyeh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Al-Shehri</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>Safety in Medical Laboratories: Perception and Practice of University Students and Laboratory Workers.</article-title>
            <source>Appl Biosaf</source>
            <year>2021</year>
            <month>Sep</month>
            <volume>26</volume>
            <issue>Suppl 1</issue>
            <fpage>S34</fpage>
            <page-range>S34-S42</page-range>
            <pub-id pub-id-type="pmid">36032652</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
